XtalPi Holdings (02228) subsidiary LCC TECHNOLOGIES enters into a drug discovery collaboration agreement with Stanford University

Zhito Finance APP news, XtalPi Holdings (02228) has announced that its wholly-owned subsidiary LCC Technologies Ltd. (LCC Technologies) and the Board of Trustees of Stanford University have entered into a drug discovery collaboration agreement. The collaboration combines Stanford University's disease biology research with LCC Technologies' automated and AI-driven small molecule drug discovery platform to accelerate and advance the development of new drugs.